BioCentury | Mar 23, 2018
Clinical News

Anthera discontinues development of Sollpura

...Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary...
...Phase III SOLUTION trial of Sollpura in the indication (see BioCentury, Jan. 6, 2017 ). Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Sollpura liprotamase (LY3031642...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Ph IIa data 2Q18 Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) / Eli Lilly and Co. (NYSE:LLY) Sollpura liprotamase...
BioCentury | Jun 16, 2017
Clinical News

Anthera starts Phase III RESULT trial of Sollpura

...Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) began the Phase III RESULT trial to evaluate oral Sollpura liprotamase (LY3031642...
...9 ). RESULT includes a 20-week extension period for patients randomized to the Sollpura arm. Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Sollpura liprotamase (LY3031642...
BioCentury | Jan 6, 2017
Clinical News

Sollpura: Ph III SOLUTION data

...data from the open-label, international Phase III SOLUTION trial in 129 patients showed that oral Sollpura...
...CFA following 7 weeks of therapy (95% CI: -16%, -8%). The non-inferiority margin was 15%. Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (Sollpura) (LY3031642...
BioCentury | Oct 3, 2016
Finance

ASH and others

...Ph III data December Eli Lilly and Co. (NYSE:LLY) / Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Sollpura liprotamase...
BioCentury | Aug 22, 2016
Clinical News

Liprotamase: Phase III ongoing

...A DSMB recommended continuation of the open-label, international Phase III SOLUTION trial comparing oral Sollpura vs...
...the trial, which has completed enrollment. Anthera has exclusive, worldwide rights to develop and commercialize Sollpura...
...Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase ( Sollpura ) ( LY3031642...
BioCentury | Oct 12, 2015
Clinical News

Liprotamase: Phase III started

...Anthera began the open-label, international Phase III SOLUTION trial to compare oral Sollpura vs. oral porcine-derived...
...therapy (PERT) in about 130 patients. Anthera has exclusive, worldwide rights to develop and commercialize Sollpura...
...Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase ( Sollpura ) ( LY3031642...
BioCentury | Aug 4, 2014
Company News

Eli Lilly, Anthera deal

...Eli Lilly granted exclusive, worldwide rights to develop and commercialize Sollpura liprotamase to Anthera. Lilly is...
...it plans to sublicense all rights, obligations and IP for the development and commercialization of Sollpura...
BioCentury | Feb 17, 2014
Clinical News

Liprotamase: Development discontinued

...that it discontinued development of liprotamase. In 2011, FDA issued a complete response letter for liprotamase...
...The product is a combination of 3 types of microbially derived pancreatic enzymes. Lilly gained liprotamase...
...2010 (see BioCentury, July 26, 2010). Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (LY3031642...
BioCentury | Dec 19, 2013
Cover Story

Oral nanoparticles

...diabetes. Altus Biologics Inc. discontinued development of the oral cross-linked pancreatic enzyme crystal biologic Trizytek liprotamase...
Items per page:
1 - 10 of 97